ReviewBiological procedures online2025
CAR T cell therapy in type 1 diabetes: what we know and what remains to be explored.
Review in Biological procedures online, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
With its increasing prevalence, diabetes continues to be a major global health concern. Insulin resistance and elevated blood glucose levels are the results of type 1 diabetes (T1D), an autoimmune disease that destroys pancreatic β cells. The underlying immune-mediated harm cannot be prevented or reversed despite a variety of therapy approaches. Recent advancements in immunotherapy are positioned as a viable option for treating T1D. A genetically modified T cell that recognizes and destroys disease-specific targets is used in chimeric antigen receptor (CAR) T-cell therapy. Its targeting of the CD19 and BCMA antigens led to a breakthrough in hematologic malignancies. The present knowledge of CAR-T treatment in T1D is expanded upon by this review. However, there are still a number of important obstacles that limit clinical application, including safety, effectiveness, and technological problems. The main achievements of CAR-T cell treatment for T1D will be discussed in this paper, along with the present challenges and potential future paths for customized CAR-T cell therapies. By combining existing knowledge with uncharted territory, this review aims to stimulate more research and innovation in the field, perhaps leading to a paradigm shift in the treatment of diabetes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.